EB104 / Estrella Biopharma - LARVOL DELTA

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination (PRNewswire) - "Estrella Immunopharma, Inc...today announced the successful closing of its business combination with Estrella Biopharma, Inc. ('Estrella'), a preclinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The resulting combined company will operate under the name Estrella Immunopharma, Inc. and will be led by Estrella Founder and CEO Dr. Cheng Liu. The combined company's common stock and warrants will trade on NASDAQ under the symbols 'ESLA,' and 'ESLAW,' respectively, effective October 2, 2023.On or about October 2, 2023, all remaining UPTD units will separate into their underlying components, which consist of one share of combined company's common stock and one-half of one warrant. The transaction was approved by UPTD's stockholders at the special meeting held on July 31, 2023."

M&A • Acute Lymphocytic Leukemia • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor